Abon Announces CLOLAR® Patent Challenge
(Northvale, N.J., July 31, 2012)
Abon Pharmaceuticals, LLC, a specialty pharmaceutical company,
today announced that it has filed an Abbreviated New Drug Application (ANDA), with a paragraph IV certification,
with the U.S. Food and Drug Administration (FDA) seeking approval to market its Clofarabine Injection, 1 mg/ml.
Abon's Clofarabine Injection is a generic equivalent of Genzyme's CLOLAR® Injection....Read More